Secondaries announced 4.6.2015
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Cerulean Pharma Inc. Symbol: CERU Price: Last trade $7.25 Trade Date: 4/7 Shares: 4.8 million Underwriter(s) Leerink Partner, Barclays Capital Co[…]